Eli Lilly Reaches $1 Trillion on Surging Weight-Loss Drug Sales

Eli Lilly has become the first drugmaker to reach a $1 trillion market valuation, driven by soaring demand for its weight loss and diabetes drugs.

This ascension is indicative of how the weight-loss drug market, which was initially a niche, has become one of the most lucrative health care markets.

The shares of the company have increased more than 35 per cent this year, which is in large part due to the huge sales of tirzepatide, branded as Mounjaro to treat type 2 diabetes and Zepbound to treat obesity.

Also Read: Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections

Over half of its entire revenue in its most recent quarter came out to in excess of 10.09 billion US dollars in combined revenue of these metabolic-health treatments at Lilly.

Its execution is also a contributor to the meteoric rise of Lilly. Although Novo Nordisk initially led in obesity medication, the Limited availability and slower scale-up of it enabled Lilly to take the lead. Lilly is now seen by investors as a potential metabolic health leader over long term and Wall Street estimates peg global weight-loss drug market at approximately 150 billion by 2030 is one area where Lilly will be in a good position to lead.

Lilly is also preparing to introduce orforglipron, its oral obesity medication, and this will allow Lilly to expand its reach to a large extent. Meanwhile, the company has negotiated with the government of the U.S. to reduce prices of Mounjaro and Zepbound- a step that can narrow the margin yet widen the access. Analysts are observing the ability of Lilly to keep this wave going as it ramps up production and avoids pricing pressures.